# RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours

> **NCT03199872** · PHASE1,PHASE2 · COMPLETED · sponsor: **RhoVac APS** · enrollment: 22 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** RV001V

## Key facts

- **NCT ID:** NCT03199872
- **Lead sponsor:** RhoVac APS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-30
- **Primary completion:** 2018-08-01
- **Final completion:** 2019-03-29
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2020-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03199872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03199872, "RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03199872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*